TRANDOLAPRIL DOSE-RESPONSE IN SPONTANEOUSLY HYPERTENSIVE RATS - EFFECTS ON ACE ACTIVITY, BLOOD-PRESSURE, AND CARDIAC-HYPERTROPHY

被引:13
作者
JOUQUEY, S [1 ]
STEPNIEWSKI, JP [1 ]
HAMON, G [1 ]
机构
[1] ROUSSEL UCLAF,CTR RECH,F-93230 ROMAINVILLE,FRANCE
关键词
TRANDOLAPRIL; ENALAPRIL; ACE INHIBITION; DOSE-RESPONSE; CARDIAC HYPERTROPHY; BLOOD PRESSURE;
D O I
10.1097/00005344-199400234-00005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The dose-related effects of trandolapril on serum angiotensin-converting enzyme (ACE) activity, blood pressure and cardiac hypertrophy were studied after 2-week oral treatment in adult spontaneously hypertensive rats. Trandolapril caused a dose-dependent decrease in mean blood pressure at doses of 0.03-3 mg/kg. inhibition of serum ACE was demonstrated by even the lowest dose (-9% at 0.003 mg/kg), was about 40% at 0.03 mg/kg, and rose to 84% at 3 mg/kg. Regression of cardiac hypertrophy (heart:body weight) was seen at doses of trandolapril as low as 0.03 mg/kg (-5.1%), which was also the minimal effective antihypertensive dose. Clear dose-response curves were observed for trandolapril from 0.03 mg/kg upwards with respect to hypotensive effect and regression of cardiac hypertrophy, which were not seen with enalapril. Enalapril had no significant effect on plasma ACE activity except at the highest dose (10 mg/kg), despite demonstrating hypotensive effects with smaller doses. These results indicate that trandolapril is a more potent (by a factor of about 30) inhibitor of ACE than enalapril (only 34% inhibition at 10 mg/kg) and causes a greater degree of regression of cardiac hypertrophy.
引用
收藏
页码:S16 / S18
页数:3
相关论文
共 10 条
[1]  
AONO J, 1988, ARCH INT PHARMACOD T, V292, P203
[2]   ANGIOTENSIN-CONVERTING ENZYME-INHIBITION, ANTI-HYPERTENSIVE ACTIVITY AND HEMODYNAMIC PROFILE OF TRANDOLAPRIL (RU-44570) [J].
BROWN, NL ;
BADEL, MY ;
BENZONI, F ;
ZANIRATO, J ;
VINCENT, JC ;
FICHELLE, J ;
WORCEL, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 148 (01) :79-91
[3]   EFFECTS OF THE ANGIOTENSIN CONVERTING ENZYME-INHIBITOR, CAPTOPRIL, IN ESSENTIAL-HYPERTENSION [J].
CAMPBELL, BC ;
SHEPHERD, AN ;
REID, JL .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 13 (02) :213-217
[4]   COMPARED PROPERTIES OF TRANDOLAPRIL, ENALAPRIL, AND THEIR DIACID METABOLITES [J].
CHEVILLARD, C ;
JOUQUEY, S ;
BREE, F ;
MATHIEU, MN ;
STEPNIEWSKI, JP ;
TILLEMENT, JP ;
HAMON, G ;
CORVOL, P .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1994, 23 :S11-S15
[5]   DIFFERENTIAL-EFFECTS OF ORAL TRANDOLAPRIL AND ENALAPRIL ON RAT-TISSUE ANGIOTENSIN-CONVERTING ENZYME [J].
CHEVILLARD, C ;
BROWN, NL ;
MATHIEU, MN ;
LALIBERTE, F ;
WORCEL, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 147 (01) :23-28
[6]  
HARJANNE A, 1984, CLIN CHEM, V30, P901
[7]  
JACKSON B, 1982, CLIN EXP PHARMACOL P, V9, P99
[8]  
Johnston C I, 1983, J Hypertens Suppl, V1, P71
[9]  
KAPLAN HR, 1984, FED PROC, V43, P1326
[10]   CORRELATION BETWEEN INHIBITION OF RENIN-ANGIOTENSIN SYSTEM AND ANTIHYPERTENSIVE EFFECT OF MK-421 AND CAPTOPRIL IN 2-KIDNEY, 1-CLIP RENAL HYPERTENSIVE RATS AFTER A SINGLE AND REPEATED ORAL-ADMINISTRATION OF MK-421 OR CAPTOPRIL [J].
OHMURA, I ;
MAKI, E ;
NARUSE, T ;
IKEDA, N ;
ASAMI, T ;
SAGAWA, N .
FOLIA PHARMACOLOGICA JAPONICA, 1985, 86 (04) :303-313